|
Sociodemographic factors
|
|
Age at survey (years) M = 78.1, SD = 6.3
|
|
≤ 70
|
375
|
11.2
|
|
> 70 ≤ 80
|
1599
|
47.8
|
|
> 80
|
1373
|
41.0
|
|
Educational level
|
|
primary, secondary - low
|
1187
|
39.8
|
|
secondary - intermediate
|
519
|
17.4
|
|
secondary - high
|
362
|
12.2
|
|
tertiary
|
911
|
30.6
|
|
Partnership
|
|
yes
|
3053
|
92.1
|
|
no
|
260
|
7.9
|
|
Children
|
|
0
|
376
|
11.5
|
|
≥ 1
|
2901
|
88.5
|
|
Clinical characteristics
|
|
Age at surgery (years) M = 62.5, SD = 6.1
|
|
≤ 55
|
399
|
11.9
|
|
> 55 ≤ 65
|
1742
|
52.1
|
|
> 65
|
1206
|
36.0
|
|
Time since surgery (years) M = 15.6, SD = 3.8
|
|
≤ 10
|
198
|
5.9
|
|
> 10 ≤ 15
|
1425
|
42.6
|
|
> 15 ≤ 20
|
1349
|
40.3
|
|
> 20
|
375
|
11.2
|
|
Second primary cancer
|
|
yes
|
430
|
12.9
|
|
no
|
2917
|
87.1
|
|
Family history of PCa
|
|
yes
|
1297
|
38.8
|
|
no
|
2050
|
61.2
|
|
PSA level at diagnosis (ng/ml)
|
|
≤ 4
|
307
|
9.9
|
|
> 4 ≤ 10
|
1870
|
60.1
|
|
> 10
|
934
|
30.0
|
|
Gleason score
|
|
2–6
|
1424
|
50.5
|
|
7, 3 + 4 = 7, 4 + 3 = 7
|
1131
|
40.0
|
|
8–10
|
269
|
9.5
|
|
Grading
|
|
G I
|
133
|
4.1
|
|
G II
|
2292
|
70.3
|
|
G III
|
833
|
25.6
|
|
Organ-confined stage at RP
|
|
yes
|
2343
|
71.0
|
|
no
|
955
|
29.0
|
|
Biochemical recurrence during follow-up
|
|
yes
|
1211
|
40.9
|
|
no
|
1749
|
59.1
|
|
Biochemical recurrence at survey
|
|
yes
|
572
|
20.0
|
|
no
|
2295
|
80.0
|
|
Discontinued PSA follow-up
|
|
yes
|
186
|
5.6
|
|
no
|
3161
|
94.4
|
|
Ongoing treatment at survey
|
|
yes
|
423
|
12.9
|
|
no
|
2864
|
87.1
|
|
Psychosocial factors
|
|
PHQ-2 (depression screening)
|
|
positive screening (≥3)
|
469
|
14.8
|
|
negative screening (< 3)
|
2707
|
85.2
|
|
GAD-2 (anxiety disorder screening)
|
|
positive screening (≥3)
|
360
|
11.4
|
|
negative screening (< 3)
|
2798
|
88.6
|
|
Perceived severity of disease
|
|
low
|
1448
|
45.0
|
|
high
|
1770
|
55.0
|
|
Well-being
|
|
low
|
1075
|
34.2
|
|
high
|
2067
|
65.8
|
|
Benefit Finding
|
|
low
|
1823
|
56.0
|
|
high
|
1429
|
44.0
|
